Research on psychedelic-assisted therapy is attracting interest from university research centers, investors Current research is promising and increasingly supportive of the benefits of psilocybin, MDNA and ketamine for depression, autism, PTSD, opioid addiction, anorexia and event anxiety associated with a terminal illness. But, the research has been on small groups and there may be unintended side effects. Inventors are still eager to find programs and clinics to invest in. From: NYTimes.com
Twin Cities-based mental health clinic offers ketamine-assisted therapy, plans to add MDMA and psilocybin versions when approved. The clinic, the Institute for Integrative Therapies, provides info about “psychedelic therapy and advocacy”; several staff have had formal training in psychedelic-assisted therapy. MinnPost posted a detailed article, including supportive and skeptical comments from local medication and addition experts.
MDMA- assisted psychotherapy for PTSD found to be significantly m ore effective than psychotherapy alone. The results of a phase III trail with randomized treatment, 90 subjects compared the experimental intervention with a placebo and only therapy. From: MedpageToday.com and NYTimes.com
. “Psilocybin Performs At Least As Well as Leading Antidepressant in Small Study” – this study has gotten attention on many of the medical/mental health news blogs that I monitor, but most emphasized that “psilocybin was not better” and seemed to miss the point – it was found to overall be as effective t treatment depression as conventional SSRI antidepressants, with “more rapid and greater reductions” in symptoms. From: Neurosciencenews.com